Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study of the Therapeutic Effectiveness of In-silico-Designed, Machine Learning Inspired, and Quantum-molecularly Coupled Personalized Neoantigenic Vaccines Microlyvaq™ in Patients With Advanced Non-small Cell Lung Cancer

NCT07285434 is registered in ClinicalTrials.gov with Biogenea Pharmaceuticals Ltd. as lead sponsor.

NCT NCT07285434
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07285434 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study of the Therapeutic Effectiveness of In-silico-Designed, Machine Learning Inspired, and Quantum-molecularly Coupled Personalized Neoantigenic Vaccines Microlyvaq™ in Patients With Advanced Non-small Cell Lung Cancer
Lead sponsor
Biogenea Pharmaceuticals Ltd.
Phase
Phase 1
Overall status
Enrolling by invitation
Start date
February 2, 2026
Completion date
February 2, 2030
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-squamous non small cell lung cancer, nsclc (non-small cell lung cancer), squamous lung cancer with fgfr1 amplification